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Abstract
Idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) belong to heterogenic group of interstitial lung diseases 
(ILD). For the reason that this group of diseases present with complex clinical non-specific features, they represent a diagnostic 
and therapeutic challenge. In this review we focus on several crucial signaling pathways participating in inflammation, fibrosis and 
EMT processes, so important in the course of ILD: TNF-a/NFkb, TGF-b/SMAD, Wnt-b-catenin and PI3K-Akt signaling. Moreover, 
this review summarizes the role of selected signaling pathways and some miRNAs which are their regulators during development 
and progression of IPF and HP. Recent advances indicate the potential role of miRNAs as a molecular markers differentiating 
clinical course of ILD. 
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Introduction 
Idiopathic pulmonary fibrosis (IPF) and 
hypersensitivity pneumonitis (HP) belong to 
heterogeneous group of interstitial lung diseases 
(ILD), where profibrotic/antifibrotic as well as 
proinflammatory/anti-inflamatory imbalance 
is postulated. However, exact etiology of these 
diseases is not fully understood, the alveolar 
epithelial cell injury and dysregulated repair 
processes are suggested [1–3].
IPF is categorized as one of the most common 
(17–86%), chronic, progressive lung disease, with 
low survival rate (median survival 3–5 years after 
diagnosis), and is currently untreatable [4–6]. Re-
cent studies have confirmed two major risk factors 
in IPF development: (1) environmental factors 
(e.g., cigarette smoking, viral infections),(2) genetic 
factors (e.g., allelic variants of VEGF, TGF-b, MUC5B, 
telomerase complex: telomerase reverse transcripta-
se (TERT), telomerase RNA (TR or TERC) [7–9]. As 
so far, several important processes involved in IPF 
are postulated: recruitment of inflammatory cells, 
deposition of extracellular matrix, accumulation 
of fibroblasts [2, 10] or activation of epithelial me-
senchymal transition (EMT) [11]. 
HP belongs to a group of immunologically 
mediated lung diseases. Repeated exposition and 
inhalation of wide variety of antigens, such as: 
bacteria (e.g., Saccharopolyspora rectivirgula), 
fungi (e.g., Trichosporon cutaneum) [12], animal 
proteins (mostly avian) [13], chemicals (e.g., 
di-isocyantes) [14] and incites hypersensitivity 
reaction of lung with granulomatous inflamma-
tion in genetically predisposed subjects [15]. 
Three key clinical forms of HP are distinguished: 
acute, subacute and chronic with frequent over-
lapping of these three forms [3]. Polymorphisms 
of transporters associated with antigen processing 
(TAP) genes are found in HP patients [16]. The 
essential reason of HP is coexistence of genetic/ 
/environmental factors which are able to stimulate 
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an exaggerated immune reaction resulting in lung 
inflammation. Following the immunopathologi-
cal changes induced in lung cells, the fibroblast 
expansion and extracellular matrix (ECM) accu-
mulation may occur [2]. 
Reassuming, chronic inflammation and EMT 
are recognized as two key pathological processes 
involved in IPF and HP development where seve-
ral signaling pathways (e.g., TNF-a/NFkb, TGF-b/ 
/SMAD, Wnt-b-catenin) are activated. Additional-
ly, the role of many different classes of miRNAs, 
which may regulate the mentioned signaling pa-
thways via gene expression at post-transcriptional 
level has been recognized. 
In this review the authors discussed the role 
of selected signaling pathways and some miRNAs 
as their regulators in the development and pro-
gression of IPF and HP. 
Signaling pathways involved in IPF  
and HP development
Inflammation
Inflammation is postulated as an initial and 
a critical factor in HP and in IPF is rather a secon-
dary process associated with fibrosis. For a long 
time it has been assumed that inflammation plays 
a direct role in pathogenesis of IPF. However, lung 
cells derived from IPF patients reveal high expres-
sion levels of genes involved in proliferation, mi-
gration, oxidative stress and remodeling. Several 
lines of evidence suggests that inflammation may 
play a key role in acute exacerbation of IPF, but 
not in chronic disease itself [17]. Additionally, 
lack of response to long-term anti-inflammatory 
treatment suggests that epithelial pathway (with 
cytokine/growth factor releasing and fibroblast 
migration) may be possible process in pulmonary 
fibrosis [2]. Selman et al. [2] proposed two diffe-
rent routes for pulmonary fibrosis development: 
a) the inflammatory pathway and b) the epithelial 
pathway. Based on the studies on human IPF and 
animal models of pulmonary fibrosis, five possible 
hypotheses for the pathogenesis of IPF have been 
proposed, underlining the controversial role of 
inflammation:1) direct inflammation hypothe-
sis, 2) matrix hypothesis in which inflammatory 
mediators are released under distant injury via 
extracellular matrix, 3) growth factor receptor 
hypothesis, where GFRs release the inflammatory 
cascade activation, 4) plasticity hypothesis based 
on EMT and multifarious interactions between 
inflammatory mediators and GFs and other key 
factors which facilitate the fibrotic phenotype, 5) 
vascular hypothesis which suggest that endothe-
lial injury activates the inflammatory cascade 
leading to fibrosis [17, 18].
In HP, the dispersed antigens provoke a hyper-
sensitivity reaction with granulomatous inflam-
mation in the distal bronchioles and alveoli [13]. 
Characterized as bronchiolocentric granulomato-
us lymphocytic alveolitis may develop to fibrosis 
in advanced stage of HP [3] In HP, the exposed 
antigens act as specific inducing factors. Imme-
diately after antigen challenge, an immunological 
response — followed by production of IL-1 and 
TNF-a by macrophages — takes place [15]. Se-
cretion of IL-1 and TNF-a may lead to adhesion 
molecule expression on leukocytes and endo-
thelial cells. What is more, macrophages secrete 
IL-8, monocyte chemoattractant protein (MCP)-
1, macrophage inflammatory protein (MIP)-1a, 
and RANTES that act as chemotactic factors for 
a variety of cells [19]. The exact mechanism of 
the disease remains unclear. It is suggested that 
tolerance may be mediated by regulatory T cells 
(Treg), a unique population of CD4+ T cells that 
play a pivotal role in the maintenance of the ba-
lance between the tissue-damaging and protective 
effects of the immune response [20]. The disease 
chronicity depends on immunopathological pro-
cesses. Patients with chronic HP show an decrease 
of CD4+ T cells and exhibit skewing toward Th2 
immunological activity [21]. It was confirmed that 
most patients have usually a  low CD4+/CD8+ 
ratios, typically < 1 in BAL — conversely that 
in sarcoidosis. 
TNF-a/NFkb signaling pathway
Tumor necrosis factor (TNF-alpha), which 
activates NF-kB family of transcription factors, 
plays an important role in the immune system 
regulation, influences the expression of cytokines, 
inducible nitric oxide synthase (iNOS), cyclo-oxy-
genase 2 (COX-2), growth factors and inhibitors 
of apoptosis [22]. The activation of NF-kB dimers 
occurs by two pathways: classical (canonical) 
and the alternative (non-canonical) pathway [23]. 
The common regulatory step in both pathways is 
activation of IkB kinase (IKK) complex encom-
passing catalytic kinase subunits (IKKa and/or 
IKKb) and the regulatory non-enzymatic scaffold 
protein NEMO (NF-kB essential modulator also 
known as IKKg). In the absence of TNF-alpha sti-
mulation, NF-kB is associated with the inhibitor 
IkB in the cytoplasm. Activation of NF-kB dimers 
(IKKa and/or IKKb) is due to IKK-mediated phos-
phorylation-induced proteasomal degradation of 
IkB. Therefore, active NF-kB transcription factor 
subunits may be relocated to the nucleus and 
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prompt target genes expression [24, 25]. It was 
recognized that TNF-a after stimulation may be 
released by macrophages, T-cells, B-lymphocytes, 
granulocytes, smooth muscle cells, eosinophils, 
chondrocytes, osteoblasts, mast cells, glial cells, 
and keratinocytes [26]. Recently, genetic studies 
have showed that polymorphism in TNF-a gene 
(TNF-308A) is associated with high TNF-a produc-
tion in vitro, and this frequency is significantly 
increased in HP patients [27]. Another study 
has demonstrated that high expression of TNF-a 
is associated with a greater risk for developing 
farmer’s lung and pigeon fancier’s lung diseases 
as a form of hypersensitivity pneumonitis [13]. 
Previous studies in human and on animal model 
have confirmed that NF-kB plays a vital role in 
inflammatory process in lung and in the path-
ogenesis of pulmonary fibrosis [28, 29]. In BLM 
(bleomycin) mice model lung inflammation and 
pulmonary fibrosis were significantly relieved by 
GLP-1 treatment, possibly through inactivation 
of NF-kB [29].Current data have demonstrated 
that NF-kB has both pro- and anti-inflammatory 
functions, permitting NF-kB to play a role both in 
the initiation and in the resolution of inflamma-
tion. Due to the fact that NF-kB takes part in the 
inflammatory response, the therapeutic strategies 
to block NF-kB signaling and arrest the disease 
process may be developed in the future [30]. 
EMT process
It is marked that the disruption of alveolar 
epithelium integrity with the presence of en-
hanced migration of fibroblasts into the alveolar 
spaces may be involved in epithelial pathway 
of IPF pathomechanism [2]. The presence of 
subepithelial fibroblast and myofibroblast loci 
in extracellular matrix followed by the abnormal 
remodeling of the ECM is considered a prognostic 
factor in IPF [31]. Type 2 EMTs is associated with 
wound healing, tissue regeneration, and organ 
fibrosis. In recent years IPF pathomechanism 
has been recognized rather as a disease charac-
terized by epithelial injury, abnormal epithelial 
healing and enhanced fibrotic response than the 
predominantly inflammatory lung disease. In 
the pathological background of IPF, epithelial 
microinjuries, increased inflammatory and/or 
pro-fibrotic cytokines followed by fibroblast 
accumulation leads to fibrotic lesion and EMT 
[32–34]. Therefore, it is postulated that excessive 
accumulation of fibroblasts generates abnormal 
epithelial-mesenchymal interactions due to EMT. 
In addition, the recent study of Yasui et al. [35] 
has shown that EMT is involved in hypersen-
sitivity pneumonitis. Based on animal model, 
authors have confirmed the correlation between 
the increased percentage of EMT cells and IL-13 
and TGF-b1 mRNA expression, as well as an in-
creased amount of collagen [35].
In human and rat alveolar epithelial cells 
and in epithelial cell lines it has been confirmed 
that EMT may be activated by the action of some 
important pathways, such as TGF-b/SMAD or 
Wnt/b-catenin signaling [9].
TGF-b/Smad signaling pathway
Many studies have demonstrated that TGF-b/ 
/Smad (transforming growth factor-b/Smad) is 
a  pleiotropic signaling pathway which play 
a crucial role in inflammation, wound healing 
and fibrotic processes [9]. It is also considered 
as a great inducer of ECM deposition and EMT 
process in tissue fibrosis via Smad-dependent 
cascade [18, 35, 36]. There are irrefutable evi-
dences that Smad2 and Smad3 play distinct roles 
in TGF-b /Smad signaling and their expression 
is different in epithelial cells and fibroblasts. 
During fibrosis, in adult fibroblast, TGF-b/Smad 
signaling pathway is working under Smad3 but 
not Smad2 [37]. It was suggested that TGF-b can 
suppress Smad 3/4 action via the overexpression 
of Smad 7 [38]. Smad 7 can act as an inhibitor 
by suppressing the phosphorylation of Smad 2 
and Smad 3 via ubiquitination by Smurf2 ubiq-
uitin-protein ligase. This process contributes to 
the degradation of the TGF-b R1 and R2 receptor 
complex, inhibiting TGF-b signaling as a final 
consequence [39]. It is also suggested that Smad 
7 gene expression influences lung airway remod-
eling and lung injuries, leading to fibrosis through 
regulating the magnitude of TGF-b signaling [40]. 
It is documented that during interstitial 
disease development, the exposure of the air-
ways to allergens results in the inflammatory 
response with the secretion of TGF-b and other 
inflammatory mediators. In consequence, the 
thickening of the lung cell membranes and lung 
damage may occur. In the next step, lung repair 
mechanism associated with the secretion of some 
mediators stimulates migration and proliferation 
of fibroblasts. Transformation to myofibroblast 
phenotype is started, which leads to pulmonary 
fibrosis, impedes gaseous exchange in the lungs 
and results in the respiratory failure [41]. 
Therefore, it is accepted that TGF-b is a main 
cytokine responsible for tissue regeneration, 
scarring and remodeling. The fibroblasts which 
are presented in a wound, as specialized myofi-
broblasts, may activate extracellular matrix via 
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elevated levels of a-smooth muscle actin (SMA), 
connective tissue growth factor (CTGF), and se-
cretion of matrix proteins, such as collagen and 
fibronectin [42]. Activation of TGF-b/SMAD sig-
naling pathway may also occur in non-canonical 
way. TGF-b can activate all three known MAPK 
pathways: extracellular signal-regulated kinase 
(ERK), p38 mitogen-activated protein kinase 
(MAPK) and c-Jun-N-terminal kinase (JNK). These 
ways of signaling further regulate Smad-inde-
pendent TGF-b responses. Moreover, p38 MAPK 
[43] and JNK [44] usually increase TGF-b/Smad 
responses. In addition to Smad and MAPK, TGF-b 
has been shown to activate PI3 kinase/Akt, Rho 
GTPase pathways and cooperate with Wnt and 
Notch [45]. The latest data show that pro-fibrotic 
effects of TGF-b are mediated through upregula-
tion of its downstream effector Connective Tissue 
Growth Factor (CTGF). TGF-b-induced expression 
of CTGF stimulates myofibroblast differentiation 
and collagen synthesis [46]. On the other hand, 
CTGF enhances the activity of TGF-b leading to 
the increased binding to TbRI and TbRII [47]. 
The CTGF expression was related to fibroblast 
proliferation, cellular adhesion, angiogenesis, and 
synthesis of ECM [48]. It is expressed in various 
types of cells, including: epithelial, vascular 
smooth muscle, and fibroblasts also in lung [48, 
49]. It was documented that higher CTGF level 
contributes to expression of a-smooth muscle 
actin (a-SMA) and the myofibroblast phenotype 
in tissue repair or development of connective 
tissues [50, 51]. What is more, CTGF appears to 
play a critical role in mediating many important 
fibroproliferative effects of TGF-b, including the 
pathogenesis of fibrotic disorders [52–54].On the 
other hand, other pro-inflammatory cytokines, 
e.g., TNF-a or IFN-g, are expressed in macro-
phages during the wound healing. They suppress 
matrix genes activities and act as antifibrotic fac-
tors [42]. Reassuming, biological effects of TGF-b 
in lung epithelium include control of airway 
remodeling, supervision of bronchial fibrosis and 
wound healing [55]. 
The activity of signaling pathways induced 
by TGF-b depends on cell type, cell differentia-
tion, interaction with other signaling pathways 
(PI3K/Akt or Wnt/b-catenin) and individual ge-
netic predispositions.
In relation to therapy glucocorticoids (GCs) 
are among the first-line therapeutics in inflamma-
tory diseases. They are responsible among others 
for inhibition of phagocytosis and lysosomal 
breakdown. They can also reduce the number of 
lymphocytes, eosinophils, and monocytes [56]. 
It has been documented that the SNP polymor-
phisms in NR3C1 gene (glucocorticoid receptor) 
don’t influence the secretion of many factors, 
such as: TGF-b, GM-CSF, VEGF, IL-1, IL-2, IL-3, 
IL-4, IL-5, IL-12, IL-13, IL-16, IL-17. On the other 
hand, in contrary, the study carried out by Panek 
et al. [56], has documented that SNPs in NR3C1 
gene intensify non-sensitivity to GCs in asthmatic 
patients. It should be emphasized that Tth111I 
and N363S polymorphisms also significantly 
modulate the level of TGF-b1 in patients with 
asthma, who have been treated with GCs.
PI3K-Akt signaling pathway 
It is commonly known that PI3K/Akt (phos-
phatidyl inositol 3-kinase/ v-akt murine thymoma 
viral oncogene homolog 1) signaling pathway re-
gulates cell growth, proliferation and apoptosis. 
In lung fibrosis in IPF patients, the PI3K/Akt via 
Akt is abnormally activated under mechanisms 
modulating the activity of the PI3K-AKT-FOXO3a 
axis, while PTEN – the main inhibitor of PI3K/
Akt signaling — is downregulated [9]. The me-
chanism of fibrosis regulation via PI3K/Akt is 
not fully understood but it has been recognized 
that during tissue repair, overgrowth of fibro-
blasts and type I collagen — as a complex with 
a2b1 integrin — are eliminated by apoptosis, in 
response to collagen matrix contraction. It has 
been recognized that PTEN which is activated 
during collagen matrix contraction, stimulates 
fibroblast apoptosis. Enhanced Akt activation de-
creases PTEN level and alters fibroblast survival. 
It was confirmed on in vitro model, where PTEN 
null fibroblasts presented enhanced level of Akt 
phosphorylation and therefore resistance to col-
lagenmatrix contraction-induced apoptosis [57]. 
Moreover, FOXO3a — one of the target gene for 
Akt — is recognized as a strong inhibitor of cell 
cycle and apoptosis. Therefore, FOXO3a deficien-
cy could protect IPF fibroblasts from apoptosis 
and enhanced fibrosis. What is more, in regulation 
of fibrosis process many interactions with other 
signaling pathways, such as TGF-b/Smad, MEK/
ERK or VEGF, Jak/STAT, have been documented. It 
should be pointed that this complex regulation of 
fibrosis with many interacting signaling pathways 
involved, suggests that single molecules of the 
mentioned paths may not be accepted as good 
molecular targets for therapy.
Wnt/bcatenin signaling pathway 
The Wnt-catenin signaling pathway regulates 
many biological processes, such as: fate determi-
nation, motility, polarity, primary axis formation 
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and carcinogenesis. Recent reports have shown 
that deregulated Wnt-catenin signaling has im-
portant negative consequences in embryonic 
development [58]. 
In respiratory epithelial cells, the Wnt/b- 
-catenin signaling pathway is necessary for lung 
branching and distal airway cell specification 
[59, 60]. Lately, it has been confirmed that in 
lung biopsies from IPF patients, high activation 
of the canonical Wnt/b-catenin signaling pathway 
is associated with tissue repair and fibroblast 
activation [61, 62]. 
Based on the above mentioned data, it is 
thought that Wnt/b-catenin signaling plays an 
important role in many pathological processes 
in lung, such as: inflammation, remodeling and 
fibrosis. Recently, it has been also documented 
that Wnt/b-catenin signaling is involved in the 
induction of EMT, an important step in fibrosis 
development [63]. The study of Königshoff et al. 
[64] confirmed significantly increased expression 
of Wnt1,3a, 7b and 10b, Fzd2, Fzd3, b-catenin, 
and LEF1 in IPF patients. What is more, authors 
have demonstrated that Wnt1, Wnt3a, b-cate-
nin, and GSK-3b are localized in alveolar and 
bronchial epithelium [64]. Especially Wn3a is 
recognized as a promotor of lung epithelial cell 
proliferation and myofibroblast activation [64]. 
Interestingly, the increased level of b-catenin 
and Wnt/b-catenin signaling pathway promotes 
fibroblast migration and proliferation and is 
associated with ventilator-induced pulmonary 
fibrosis in previously healthy persons [65]. The-
se data indicate that activation of b-catenin may 
be a common feature of lung fibrosis, including 
pathological process in IPF. 
It is also known that Wnt/b-catenin signaling 
pathway may link the IPF progression with other 
signaling pathways as a special cross-talk between 
them. Mainly TGF-b could trigger Wnt/b-catenin 
signaling pathway and initiate the cellular matrix 
accumulation. In Wnt/b-catenin signaling, the 
regulation of fibrosis, the nuclear translocation of 
b-catenin via the phosphorylation of ERK1/2 and 
suppression GSK-3b activity seem to be crucial [66]. 
The proposal crosstalk between signaling pathways 
involved in EMT process is shown in Figure 1.
miRNA a potential gene expression 
regulators 
It is well identified that miRNAs are able to 
post-transcriptionally regulate gene expression 
Figure 1. The proposal of a crosstalk between signaling pathways involved in EMT process. Abbreviations;TGF-b — transforming growth factor-b; 
Smad 2 — mothers against decapentaplegic homolog 2 protein; Smad 3 — mothers against decapentaplegic homolog 3 protein; Smad 4 — moth-
ers against decapentaplegic homolog 4 protein; Wnt — wingless/integration signaling; Dsh — phosphoprotein Dishevelled; GSK3 — glycogen 
synthase kinase 3; TCF/LEF-T — cell factor/lymphoid enhancing factor; GF — growth factors; PI3K — Phosphoinositide 3-kinase; Akt — Protein 
kinase B mTOR — mechanistic target of rapamycin
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Table 1. Important miRNAs regulating the selected signaling pathways in inflammation process in IPF and HP
miRNA Target Function Disease Process Reference
miR-146 IL-8 In human lung alveolar epithelial tumor A549 cells miR-146a 
negatively regulates the release of IL-8 and RANTES 
HP? inflammation [71]
miR-155 NF-kB
IFN-g
In human mesangial cells, IFN-g and TNF-a induce miR-155  
expression and regulate inflammatory and immune responses, 
HP? inflammation [74]
in almost all aspects of physiological conditions, 
such as: cell differentiation, cell growth, mobility 
and apoptosis. Therefore, miRNAs are noted as 
important factors involved in the development of 
many human diseases. Many classes of miRNAs 
exhibiting abnormal expression have been reco-
gnized as therapeutic targets. 
It is noteworthy that miRNAs can be detected 
in various biological materials, such as: tissue, 
blood, serum, plasma, body fluids. Current stu-
dies have confirmed that exosomes are “bioactive 
vesicles” that promote intercellular communica-
tion and immunoregulatory processes by trans-
porting molecules between cells [67, 68]. What 
is more, exosomal miRNAs (by being packaged in 
lipid vesicles) are protected against degradation 
and can be functionally delivered to target cells.
miRNAs have been revealed to be expressed 
in a tissue-specific and developmental stage-speci-
fic manner [69]. Also the lung has been shown to 
have a very specific miRNA expression profile. It 
has been shown that some miRNAs have characte-
ristic lung specific expression profile. For example, 
these that participate in biological processes in the 
lungs, i.e., miR-155, miR-26a, let-7, miR-29, miR-
15/miR-16, miR-223, miR-146a/b and the miR-17-
92 cluster are involved in homeostasis and in the 
lung development [70]. Other, like miR-146a/146b 
[71], miR-155 [72] are important in pulmonary 
inflammation. All mentioned miRNAs may show 
up/down regulation in lung. Moreover, it is do-
cumented that smoking also influences miRNA 
expression levels. Expression profiling study in 
the rats exposed to environmental cigarette smoke 
revealed 24 downregulated miRNAs (especially 
let-7 family, miR-10, -26, -30, -34, -99, -122, -123, 
-124, -125, -140, -145, -146, -191, -192, -219, -222, 
and -223) when compared to control group [73]. 
In the respiratory system, miRNAs are important 
in normal pulmonary development and lung ho-
meostasis. Recent studies have also documented 
that altered miRNAs expression profiles may be 
related to pathological processes within the lung, 
such as inflammatory diseases or lung fibrosis.
Many data have demonstrated that miRNAs 
are involved in the regulation of adaptive immune 
system: development, differentiation of B and T 
cells, proliferation of monocytes and neutrophils, 
antibody production or release of inflammato-
ry mediators. They may work in the negative 
feedback regulation of inflammation following 
activation by the innate immune system. In IPF 
and HP diseases, miRNAs have been recognized 
as negative regulators of many signaling pathways 
involved in inflammation process (Table 1).
Also, miRNA dysregulation has been re-
cognized in fibrotic disorders, as regulators of 
tissue injury and fibrosis, and especially as EMT 
controlling factors in IPF and HP (Table 2).
Interestingly, the special attention has fo-
cused on significance of miR-21 in pulmonary 
fibrosis. The study on animal model has confir-
med that miR-21 is upregulated in the lungs of 
mice with bleomycin-induced fibrosis. Moreover, 
miR-21 has been shown to be upregulated also in 
the lungs of patients with idiopathic pulmonary 
fibrosis, under pro-fibrogenic activity of TGF-b 
[81]. Additionally, let-7d has been recognized as 
significantly decreased in idiopathic pulmonary 
fibrosis, which correlates with increased collagen 
deposition during EMT in mouse lung [76]. Also 
miR-155 is involved in both inflammatory and 
pulmonary fibrosis [81]. Functions of the mentio-
ned miRNAs are summarized in Tables 2 and 3. 
Conclusions 
Our review summarizes the current knowled-
ge on important signaling pathways involved in 
the pathogenesis of IPF and HP, with an emphasis 
on two important processes, i.e., inflammation 
and EMT. We underline a  fundamental role of 
some miRNAs which have the ability to modula-
te multiple genes and pathways. In recent years 
there has also been an explosion of reports on 
miRNA involvement in lung diseases, including 
interstitial lung diseases (ILD), which may have 
diagnostic and future therapeutic value. We focus 
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Table 3. Important miRNAs regulating the selected signaling pathways in both inflammation and EMT processes in IPF and HP
miRNA Target Function Disease Process Reference
miR-21 Smad7
IL1-b
Inhibits pro-fibrogenic activity of TGF-b pathway in fibroblasts
miR-21 acts as an anti-inflammatory agent within a negative  
regulatory loop: NF-kB activity is necessary for miR-21 induction, 
but by targeting PDCD4, miR-21 inhibits NF-kB and its  
pro-inflammatory transcriptional targets.
IPF
HP? 
EMT
inflammation
[82]
[83]
miR-17~92 
cluster
TGF-b Regulates lung epithelial
cell development
IPF EMT
inflammation
[84]
miR-200 
family
E-cadherin
ZEB1
ZEB2
TGF-b
These miRNAs are regulators/inhibitors of EMT and act to main-
tain the epithelial phenotype by targeting the expression of the 
E-cadherin transcriptional repressors, ZEB1 and ZEB2
IPF
HP?
Inflammation 
EMT
[85, 86] 
Table 2. Important miRNAs regulating the selected signaling pathways in EMT process in IPF and HP 
miRNA Target Function Disease Process Reference
miR-424 Smurf2 Enhances a-SMA expression, regulates the myofibroblast 
differentiation during EMT by increasing the activity of TGF-b 
pathway
IPF EMT [75]
let-7d HMGA2
TGF-b1
Antifibrotic agent
Increases the collagen deposition during  EMT
IPF EMT [76]
miR-326 TGF-b
Smad 7
Fibrotic agent IPF EMT [77]
miR-154 FZD4 Promotes proliferation and migration in lung fibroblast IPF EMT [78]
miR-375 FZD8 regulates AEC trans-differentiation through the Wnt/b-catenin 
pathway
IPF EMT [79]
miR-199a TGF-b1  Pathogenic activation of fibroblast IPF EMT [80]
Figure 2. MiRNAs that regulate inflammation, EMT or both processes in ILD pathogenesis
on some miRNAs which control the processes 
of inflammation (miR-146, miR-155) and EMT 
(miR-424, let-7d, miR-326, miR-154, miR-375, 
miR-199) in lung disorders; especially IPF and 
HP. MiRNAs that regulate inflammation, EMT 
or both processes in ILD are shown in Figure 2. 
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Based on the progress in molecular biology 
and in the area of understanding of inflammatory 
and fibrosis processes in lung and other organs, it 
seems highly likely that studies focused on miR-
NA role in the pathogenesis of ILD are extremely 
important and necessary. 
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